ArticleInflammation2012
Effects of lower concentration thrombin on high-mobility group box 1 protein-mediated inflammatory responses.
Article in Inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome.BMC infectious diseases · 2018Article
- Observational
- HMGB-1 as a novel predictor of disease severity and prognosis in patients with hemorrhagic fever with renal syndrome.Mediators of inflammation · 2015Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a late mediator of inflammation, the high-mobility group box 1 protein (HMGB1) plays a key role in the inflammatory responses to tissue injury and infection by inducing and extending the production of proinflammatory cytokines. It has been observed that lower concentration thrombin mediates anti-inflammatory activities. The aim of this study was to investigate whether lower concentration thrombin could modulate HMGB1 expression and could inhibit HMGB1-mediated inflammatory responses in human umbilical vein endothelial cells (HUVECs). Here, results showed that lower concentration thrombin or thrombin receptor agonist peptide inhibits lipopolysaccharide-induced HMGB1 release from HUVECs. And lower concentration thrombin has inhibitory effects not only on the expression of cell adhesion molecules but also on neutrophils adhesion and migration toward HUVECs in response to HMGB1. Interestingly, the HMGB1-induced nuclear factor kappa B activation and tumor necrosis factor-alpha release from HUVECs were inhibited by lower concentration thrombin. Given these results, lower concentration thrombin could be a strong candidate as a therapeutic agent for various systemic inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.